Gossamer Bio (NASDAQ:GOSS) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research note published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.

GOSS has been the topic of several other research reports. The Goldman Sachs Group reiterated a buy rating and issued a $8.00 price target on shares of Gossamer Bio in a report on Monday, June 17th. Oppenheimer assumed coverage on Gossamer Bio in a report on Tuesday, June 25th. They issued an outperform rating and a $9.00 target price on the stock. Finally, Wedbush restated an outperform rating and set a $4.00 price target on shares of Gossamer Bio in a research note on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Gossamer Bio currently has a consensus rating of Buy and an average price target of $9.20.

Gossamer Bio Stock Up 5.3 %

Gossamer Bio stock opened at $0.96 on Tuesday. The company has a market capitalization of $217.12 million, a PE ratio of -0.91 and a beta of 1.95. Gossamer Bio has a 12-month low of $0.45 and a 12-month high of $1.60. The firm’s fifty day moving average is $0.93 and its 200 day moving average is $0.92. The company has a quick ratio of 8.21, a current ratio of 8.21 and a debt-to-equity ratio of 2.42.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Monday, August 12th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $95.84 million for the quarter, compared to analysts’ expectations of $160.00 million. As a group, sell-side analysts predict that Gossamer Bio will post -0.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Gossamer Bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC grew its stake in shares of Gossamer Bio by 51.6% in the 1st quarter. Acadian Asset Management LLC now owns 2,736,385 shares of the company’s stock worth $3,227,000 after acquiring an additional 931,248 shares in the last quarter. Platinum Investment Management Ltd. lifted its position in shares of Gossamer Bio by 29.8% during the 4th quarter. Platinum Investment Management Ltd. now owns 6,954,110 shares of the company’s stock worth $6,346,000 after buying an additional 1,596,332 shares in the last quarter. Corient Private Wealth LLC boosted its stake in shares of Gossamer Bio by 48.9% in the 4th quarter. Corient Private Wealth LLC now owns 2,937,931 shares of the company’s stock worth $2,681,000 after buying an additional 965,092 shares during the last quarter. Monaco Asset Management SAM grew its holdings in shares of Gossamer Bio by 390.3% in the second quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock valued at $2,456,000 after acquiring an additional 2,170,104 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its holdings in Gossamer Bio by 27.2% during the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock worth $84,000 after acquiring an additional 20,000 shares during the period. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.